spravato esketamine - Search News

FDA approves Spravato

Times Now on MSN · 2h

What is Spravato, an FDA-approved First Standalone Esketamine-based Nasal Spray Monotherapy for Depression?

The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and manufactured by Johnson & Johnson, this ketamine-based drug has been approved as a standalone treatment for major depressive disorder or MDD.

Can a Nasal Spray Really Help Treat Depression? Here's What to Know About Spravato

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Medical Xpress · 7h

FDA approves nasal spray for treatment-resistant depression

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral antidepressants, according to a news release issued by Johnson & Johnson.

Hosted on MSN9h

J&J’s Spravato receives FDA label expansion for depression monotherapy

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

pharmaphorum18h

J&J's Spravato gets another lift with new FDA approval

The accelerating sales growth of Johnson & Johnson's Spravato could go up yet another gear after the FDA approved a third ...

J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results